Principal Securities, Inc. Halozyme Therapeutics, Inc. Transaction History
Principal Securities, Inc.
- $3.63 Trillion
- Q2 2024
A detailed history of Principal Securities, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 1,807 shares of HALO stock, worth $112,612. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,807
Previous 971
86.1%
Holding current value
$112,612
Previous $39.5 Million
139.53%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
488Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.1 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$803 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$362 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$252 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$232 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.68B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...